Back to Menu
Colon Cancer Treatment Modalities
1.Endoscopic mucosal resection (EMR)
Suitable for early intramucosal carcinoma, with minimal trauma and rapid recovery; strict patient selection and close follow-up are required.
2.Laparoscopic radical colectomy
A mainstream minimally invasive approach, associated with less pain and faster recovery, with oncologic outcomes comparable to open surgery.
3.Open radical colectomy
Indicated for large tumors, deep invasion, or cases in which minimally invasive procedures are difficult; provides clear exposure.
4.Adjuvant chemotherapy
Administered postoperatively to eradicate micrometastases. Common regimens include FOLFOX and XELOX, reducing recurrence risk.
5.Neoadjuvant chemotherapy
Administered preoperatively to downstage tumors and increase the likelihood of curative resection, particularly in locally advanced disease.
6.Targeted drug therapy
Anti-EGFR agents are used for RAS wild-type tumors; anti-angiogenic agents combined with chemotherapy can prolong survival.
7.Immune checkpoint inhibitors
PD-1 monoclonal antibodies are used for advanced dMMR/MSI-H disease, and some patients can achieve long-term survival.
8.Radiotherapy
Less commonly used for colon cancer; in selected situations, it may be applied for locally advanced disease or palliative pain control.
9.Local treatment for liver metastases
Surgical resection and radiofrequency/microwave ablation can significantly improve outcomes in patients with hepatic metastases.
10.Interventional therapy
Hepatic arterial infusion chemotherapy and/or embolization can control unresectable liver metastases and create opportunities for conversion therapy.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that the incidence of colon cancer continues to rise. Early colonoscopic screening and standardized stage-based management are pivotal. Treatment selection based on molecular subtyping — integrating surgery, chemotherapy, and targeted therapy / immunotherapies — together with MDT-based multidisciplinary collaboration, can substantially improve treatment outcomes and quality of survival.
Colon Cancer Treatment Modalities
1.Endoscopic mucosal resection (EMR)
Suitable for early intramucosal carcinoma, with minimal trauma and rapid recovery; strict patient selection and close follow-up are required.
2.Laparoscopic radical colectomy
A mainstream minimally invasive approach, associated with less pain and faster recovery, with oncologic outcomes comparable to open surgery.
3.Open radical colectomy
Indicated for large tumors, deep invasion, or cases in which minimally invasive procedures are difficult; provides clear exposure.
4.Adjuvant chemotherapy
Administered postoperatively to eradicate micrometastases. Common regimens include FOLFOX and XELOX, reducing recurrence risk.
5.Neoadjuvant chemotherapy
Administered preoperatively to downstage tumors and increase the likelihood of curative resection, particularly in locally advanced disease.
6.Targeted drug therapy
Anti-EGFR agents are used for RAS wild-type tumors; anti-angiogenic agents combined with chemotherapy can prolong survival.
7.Immune checkpoint inhibitors
PD-1 monoclonal antibodies are used for advanced dMMR/MSI-H disease, and some patients can achieve long-term survival.
8.Radiotherapy
Less commonly used for colon cancer; in selected situations, it may be applied for locally advanced disease or palliative pain control.
9.Local treatment for liver metastases
Surgical resection and radiofrequency/microwave ablation can significantly improve outcomes in patients with hepatic metastases.
10.Interventional therapy
Hepatic arterial infusion chemotherapy and/or embolization can control unresectable liver metastases and create opportunities for conversion therapy.
Conclusion
Jinshazhou Hospital of Guangzhou University of Chinese Medicine emphasizes that the incidence of colon cancer continues to rise. Early colonoscopic screening and standardized stage-based management are pivotal. Treatment selection based on molecular subtyping — integrating surgery, chemotherapy, and targeted therapy / immunotherapies — together with MDT-based multidisciplinary collaboration, can substantially improve treatment outcomes and quality of survival.